Foundayo: What to Know About the New Oral Weight-Loss Medicine

Foundayo is the brand name for orforglipron, a once-daily tablet from Eli Lilly that the US FDA approved on April 1, 2026, for chronic weight management in eligible adults. It became available in US pharmacies the following week. It has drawn attention because it's a small-molecule GLP-1 medicine, not a peptide like semaglutide or tirzepatide, and that changes how it's taken. Approval is a specific regulatory decision, though, not a guarantee that it's right for every person.

Who it's approved for

The US label covers adults with obesity, or adults with overweight plus at least one weight-related health condition, used alongside a reduced-calorie diet and more physical activity. It shouldn't be combined with another GLP-1 medicine. As of October 2026, approval, availability, price and insurance coverage outside the United States may differ.

How it's taken

This is the headline difference from the Wegovy pill: Foundayo is taken with or without food, and its label doesn’t include the empty-stomach, small-sip-of-water and 30-minute-wait rules that come with the Wegovy pill. Tablets are swallowed whole. It starts at 0.8 mg once daily and steps up at least every 30 days (2.5 mg, then 5.5 mg), after which the prescriber may move to 9 mg, 14.5 mg or a maximum of 17.2 mg depending on response and tolerability. If 7 or more doses in a row are missed, the label says to restart at a lower dose, so check with your prescriber before simply picking back up.

What the trials showed

The label describes two 72-week placebo-controlled trials:

• Adults without diabetes: average weight change was −11.1% at the top 17.2 mg dose versus −2.1% with placebo (−7.4% at 5.5 mg and −8.3% at 9 mg).
• Adults with type 2 diabetes: −9.6% at 17.2 mg versus −2.5% with placebo.

That's meaningful weight loss, but on average less than the injectable trials of semaglutide 2.4 mg or tirzepatide reported. Those were different trials with different people, though, so the only fair comparisons are head-to-head studies.

Side effects and safety

The most common side effects were digestive (nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, bloating, burping and reflux), plus headache, fatigue and hair loss. They were more frequent while the dose was going up. About 8% of people stopped Foundayo because of side effects, compared with 3% on placebo, and the rate was higher at higher doses. Our nausea guide has practical food tips.

Like other GLP-1 medicines, it carries a boxed warning about thyroid C-cell tumors and shouldn't be used by people with a personal or family history of medullary thyroid cancer or MEN 2. Other label warnings include pancreatitis, gallbladder problems, severe digestive reactions, dehydration-related kidney injury, low blood sugar when combined with insulin or sulfonylureas, and allergic reactions.

Two practical points stand out:

• Drug interactions. Because orforglipron is broken down by the liver enzyme CYP3A4, some medicines that affect that enzyme change the maximum dose or shouldn't be combined. Bring a full list of your medicines and supplements to your prescriber or pharmacist.
• Birth-control pills. The label advises switching to a non-oral method or adding a barrier method for 30 days after starting and after each dose increase. It also says to stop Foundayo if pregnancy is recognized.

How to compare it with other options

When comparing Foundayo with the Wegovy pill or injectable treatments, look at the study population, how long the trial lasted, average percentage weight change, how many people stopped because of side effects, and whether comparisons were head-to-head. Don't assume the biggest headline number is the best fit for you; daily routine, other medicines, side effects and cost matter too. Our overview of the new weight-loss medicines of 2026 puts these options side by side.

Questions for your prescriber

Is Foundayo approved and available where I live? Does it fit my goals and health history? Do any of my current medicines interact with it? Which side effects should I watch for, and how will progress be judged? And avoid buying anything online that only claims to be orforglipron or a "research" version; get it from a licensed pharmacy with a prescription.

The key story is another oral option in a fast-moving field. Approval status, trial evidence, practical fit and personal medical advice are separate questions worth asking one at a time.